LC-MS/MS法测定坦索罗辛在比格犬血浆中的浓度及其缓释制剂的药动学研究

中国临床药理学与治疗学 ›› 2011, Vol. 16 ›› Issue (8): 884-889.

LC-MS/MS法测定坦索罗辛在比格犬血浆中的浓度及其缓释制剂的药动学研究

邢小敏¹, 梁超峰², 吴淳¹, 潘碧妍¹, 侯雪英¹, 谢智勇¹

¹中山大学药学院药物分析与质量评价实验室,广州 510006,广东;
²广州市医药工业研究院,广州 510240,广东

收稿日期:2011-06-30 修回日期:2011-08-07 出版日期:2011-08-26 发布日期:2011-09-07
通讯作者: 谢智勇,男,副教授,硕士生导师,研究方向:药物代谢与药代动力学。Tel: 020-39943047 E-mail: xiezy2074@yahoo.com
作者简介:邢小敏,女,硕士研究生,研究方向:体内药物分析。Tel: 020-39943047 E-mail: xingxiaomin826@sina.com
基金资助:
“重大新药创制”国家科技重大专项(2009ZX09304-003,2009ZX09501-017);中山大学青年教师培育项目

Determination of tamsulosin in dog plasma by LC-MS/MS and study on its pharmacokinetics

XING Xiao-min¹, LIANG Chao-feng², WU Chun¹, PAN Bi-yan¹, HOU Xue-ying¹, XIE Zhi-yong¹

¹School of Pharmaceutical Sciences, Sun Yat - Sen University, Guangzhou 510006, Guangdong, China;
²Guangzhou Institute of Pharmaceutical Industry, Guangzhou 510240, Guangdong, China

Received:2011-06-30 Revised:2011-08-07 Online:2011-08-26 Published:2011-09-07

摘要/Abstract

摘要： 目的: 建立坦索罗辛血药浓度LC-MS/MS测定方法,并研究坦索罗辛缓释制剂在比格犬体内的药代动力学。方法: 6只比格犬空腹单次口服给予含有 0.4 mg 的盐酸坦索罗辛缓释胶囊,给药前(0 h)、给药后不同时间点各采血 0.3 mL,分离血浆后,加入内标愈创木酚甘油醚,经乙酸乙酯萃取,以甲醇:水:甲酸(80∶20∶0.2,V/V/V)为流动相,在反相C₁₈色谱柱进行分离。采用电喷雾离子源(ESI源)的正离子方式检测,扫描方式为选择反应监测(SRM),用于定量分析的离子反应为m/z 409.0→m/z 228.0(坦索罗辛)和m/z 199.0→m/z 125.0(内标,愈创木酚甘油醚)。结果: 坦索罗辛在线性范围内 0.05~10.0 ng/mL 线性良好,定量下限为 0.05 ng/mL,批内、批间精密度(RSD)均小于 13.4%。盐酸坦索罗辛缓释制剂 0.4 mg 口服给药后AUC_{0-24 h} 为 (7.82±1.92) ng·h·mL^-1、AUC_0-∞为 (8.04±2.02) ng·h·mL^-1、t_1/2 为(2.96±2.13) h。结论: LC-MS/MS法灵敏度高、分析快速,适用于比格犬血浆中坦索罗辛的药动学研究,坦索罗辛缓释胶囊口服给药后半衰期短,消除快。

关键词: 高效液相色谱-串联质谱法, 坦索罗辛, 药动学

Abstract: AIM: To establish an LC-MS/MS method for the determination of tamsulosin in dog plasma and to study pharmacokinetics of tamsulosin hydrochloride controlled release capsules in Beagle dogs.METHODS: The 0.3 mL of blood samples were collected at before and different times after six Beagle dogs were received an oral dose of 0.4 mg tamsulosin.Tamsulosin and the internal standard (guaifenesin) were extracted by ethyl acetate from dog plasma, and separated on a Thermo C₁₈ column using methanol-water-formic acid (80∶20∶0.2, V/V/V) as mobile phase. Elecrospray ionization (ESI) source was applied and operated in the positive ion mode. Quantification was performed using selected reaction monitoring (SRM) mode. The transitions for tamsulosin and guaifenesin were m/z 409.0→m/z 228.0 and m/z 199.0→m/z 125.0, respectively.RESULTS: The linear concentration ranges of the calibration curves for tamsulosin were 0.05-10.0 ng/mL.The lower limit of quantification was 0.05 ng/mL. The intra- and inter-run relative standard deviations (RSD) were lower than 13.4%.The pharmacokinetic parameters of tamsulosin was as follows: AUC_{0-24 h}(7.82±1.92) ng·h·mL^-1, AUC_0-∞(8.04±2.02) ng·h·mL^-1,t_1/2(2.96±2.13) h.CONCLUSION: The method is simple,high sensitivity and is proved to be suitable for pharmacokinetic study for tamsulosin in Beagle dogs.The half-life is short, and its clearance from dog body is very quick.

Key words: LC-MS/MS, Tamsulosin, Pharmacokinetics

中图分类号:

R969.1

邢小敏, 梁超峰, 吴淳, 潘碧妍, 侯雪英, 谢智勇. LC-MS/MS法测定坦索罗辛在比格犬血浆中的浓度及其缓释制剂的药动学研究[J]. 中国临床药理学与治疗学, 2011, 16(8): 884-889.

XING Xiao-min, LIANG Chao-feng, WU Chun, PAN Bi-yan, HOU Xue-ying, XIE Zhi-yong. Determination of tamsulosin in dog plasma by LC-MS/MS and study on its pharmacokinetics[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(8): 884-889.

参考文献

[1] Honda K, Nakagawa C. Alpha-1 adrenoceptor antagonist effects of the optical isomers of YM-12617 in rabbit lower urinary tract and prostate [J]. J Pharmacol Exp Ther, 1986, 239(2): 512-517.
[2] 余晋荣. 盐酸坦索罗辛的临床应用[J]. 海峡药学, 2006,18(1): 143-145.
[3] 杨劲,丁黎,郝歆愚,等. 盐酸坦洛新缓释胶囊在人体内的药动学和生物等效性[J]. 中国临床药学杂志,2005, 14(6): 339-342.
[4] 刘丽鹤,王鹏,李好枝. 盐酸坦洛新血药浓度测定方法及其药动学研究进展[J]. 中国药学杂志,2003, 37(7): 488-490.
[5] Soeishi Y, Kobori M, Kobayshi S, et al. Sensitive method for the determination of tamsulosin in human plasma using HPLC with fluorescence detection[J]. J Chromatogr, 1990, 533: 291-296.
[6] 樊慧蓉,谷元,司端运,等. 高灵敏度LC-MS/MS法测定犬血浆中的坦洛新[J]. 药学学报, 2007, 42(8): 872-876.
[7] Qi M, Wang P, Liu L. Determination of tamsulosin in dog plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2004, 805(1): 7-11.
[8] Ding L, Li L, Tao P, et al. Quantitation of tamsulosin in human plasma by liquid chromatography-electrospray ionization mass spectrometry [J].J Chromatogr B Analyt Technol Biomed Life Sci, 2002, 767(1): 75-81.
[9] Pekka K, Olavi P, Esa L, et al. Determination of tamsulosin in human aqueous humor and serum by liquid chromatography-electrospray ionization tandem mass spectrometry [J]. J Pharm Biomed Anal, 2007, 43(2): 606-612.
[10] Ramakrishna NV, Vishwottam KN, Manoj S, et al. Rapid, simple and highly sensitive LC-ESI-MS/MS method for the quantification of tamsulosin in human plasma[J]. Biomed Chromatogr, 2005, 19(10): 709-719.
[11] Nageswara RR, Kumar Talluri MV, Narasa Raju A, et al. Development of a validated RP-LC/ESI-MS-MS method for separation, identification and determination of related substances of tamsulosin in bulk drugs and formulations[J]. J Pharm Biomed Anal, 2008, 46(1): 94-103.
[12] Matsushima H, Takanuki KI, Kamimura H, et al. Highly sensitive method for the determination of tamsulosin hydrochloride in human plasma dialysate, plasma and urine by high-performance liquid chromatography-electrospray tandem mass spectrometry[J]. J Chromatogr B Biomed Sci Appl, 1997, 695(2): 317-327.
[13] Taguchi K, Schafers RF, Michel MC. Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics [J]. Br J Clin Pharmacol, 1998, 45(1): 49-55.
[14] Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies [J]. Eur J Drug Metab Pharmacokinet, 1991, 16(4): 249-255.

[1]	武玉洁, 赵程程, 席庆. 蒙特卡洛模拟评价替加环素治疗革兰阴性菌感染给药方案[J]. 中国临床药理学与治疗学, 2023, 28(9): 1027-1033.
[2]	黄志伟, 李熠, 徐晓勇, 张蕾, 沈一峰, 李华芳. 五种群体药动学分析工具计算结果的比较[J]. 中国临床药理学与治疗学, 2023, 28(5): 525-535.
[3]	燕强勇, 向大雄, 朱荣华, 杨玲凤, 阳喜定, 李晶晶, 范晓, 刘赛, 熊守军, 方平飞. 盐酸西那卡塞片在中国健康人群的生物等效性研究[J]. 中国临床药理学与治疗学, 2023, 28(2): 171-177.
[4]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[5]	李雪静, 江金平, 李思凝, 万林飞, 周响响, 杨梿, 兰轲. 一项在中国精神分裂症受试者中评估氯氮平片的生物等效性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1121-1130.
[6]	张进华, 刘茂柏, 蔡铭智, 郑英丽, 劳海燕, 向倩, 都丽萍, 朱珠, 董婧, 左笑丛, 李新刚, 尚德为, 陈冰, 叶岩荣, 王玉珠, 高建军, 张健, 陈万生, 谢海棠, 焦正. 模型引导的华法林精准用药：中国专家共识（2022版）[J]. 中国临床药理学与治疗学, 2022, 27(11): 1201-1212.
[7]	贾元威, 沈杰, 储冀汝, 张翠锋, 谢海棠, 杨斌, 李相鸿, 郑丹丹, 赵静惠. 豆腐果苷及其代谢产物时辰药动学研究[J]. 中国临床药理学与治疗学, 2021, 26(9): 986-994.
[8]	徐国防, 高盼, 刘平, 赖耀文, 李广辉, 赵岳, 张永玲, 李晓苏, 齐琦. 肿瘤患者个体差异对卡培他滨药物代谢动力学影响[J]. 中国临床药理学与治疗学, 2021, 26(3): 305-311.
[9]	章思亮, 胡琳璘, 邵华, 陈西敬. 性别差异对精神药物作用影响的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(3): 324-331.
[10]	张苗, 刘倩, 么雪婷, 刘东阳. 基于口服吸收生理药动学模型的创新药早期临床食物影响研究探索[J]. 中国临床药理学与治疗学, 2021, 26(12): 1426-1429.
[11]	焦正, 李新刚, 尚德为, 董婧, 左笑丛, 陈冰, 刘剑敏, 潘雁, 周田彦, 张菁, 刘东阳, 李禄金, 方翼, 马广立, 丁俊杰, 赵维, 陈锐, 相小强, 王玉珠, 高建军, 谢海棠, 胡蓓, 郑青山. 模型引导的精准用药：中国专家共识（2021版）[J]. 中国临床药理学与治疗学, 2021, 26(11): 1215-1228.
[12]	郭仙忠, 林荣芳, 林玮玮. 基于群体药动学模型的万古霉素个体化给药软件研制及应用[J]. 中国临床药理学与治疗学, 2021, 26(1): 30-39.
[13]	林忠, 谢群莉, 戴淑萍, 陈静, 林菲阳, 朱燕舞, 余国亮, 张远怀, 崔可. 中国成年患者利奈唑胺治疗群体药动学研究[J]. 中国临床药理学与治疗学, 2020, 25(9): 992-999.
[14]	向荣凤, 孙凤军, 熊丽蓉, 喻明洁, 戴青, 陈勇川. 左旋泮托拉唑钠肠溶片在健康人体内的药代动力学和药效学研究[J]. 中国临床药理学与治疗学, 2020, 25(8): 903-909.
[15]	李智慧, 刘静彦, 邱雯, 陈红. 氟康唑胶囊在中国健康受试者的人体生物等效性研究[J]. 中国临床药理学与治疗学, 2020, 25(8): 910-915.